Counterargument
What if butyrate supplementation fails despite intact host capacity?
Oral butyrate supplementation has produced inconsistent clinical results, which may seem to contradict the bioenergetic framing.
Where it is valid
Trials of oral or rectal butyrate showing limited symptomatic benefit in unselected populations.
What it challenges
The naive interpretation that butyrate supplementation alone should resolve host-capacity deficits.
Host Capacity Model response
HCM does not claim oral butyrate is a therapy. It claims colonocyte bioenergetic state matters mechanistically. Restoration is a multi-axis context (substrate availability, mitochondrial function, inflammatory tone, microbial fermentation), not a single supplement.
Unresolved questions
- What delivery and timing of substrate-supportive context (if any) is mechanistically meaningful?
- How should host-capacity be assessed before considering substrate-related context?
Evidence that would resolve this
- Trials of multi-axis substrate-supportive context in stratified host-capacity-fit cohorts.